COM701 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors. The study is designed to evaluate the safety and tolerability of COM701 as monotherapy and in combination with a PD-1 inhibitor. Additional endpoints include evaluation of PK/PD and preliminary clinical activity in certain tumor types such as non-small cell lung, breast, ovarian and endometrial cancer. Preclinical data demonstrate that these tumor types express a high level of the biomarkers PVRIG and PVRL2.
The Phase 1 study is currently enrolling patients in the United States and is expected to include approximately 140 patients. The study is enrolling patient in Arm A (monotherapy dose escalation) and Arm B (combination dose escalation). Additional Information on the COM701 Phase 1 clinical trial can be found here.
Preliminary results from the monotherapy dose escalation study were presented at SITC 2019. These data demonstrated that COM701 is well-tolerated with initial signals of anti-tumor activity. Additional information can be found here.